Arrowhead Pharmaceuticals, Inc. (ARWR) stock
ARWRNasdaqPharmaceutical PreparationsFiscal year ends September 30
$47.78+0.63 (+1.34%)
Close on Nov 13, 2026Market cap $6.75BP/E –Yield –
Arrowhead Pharmaceuticals ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Arrowhead Pharmaceuticals's ebitda for the twelve months ending Sep 30, 2026 was -$682.47M, down 666.1% year over year. For fiscal 2026 it was -$682.47M, down 666.1% from the year before. The highest annual figure on record is $120.55M in fiscal 2025.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Sep 30, 2026 | -$682.47M | -666.1% |
| FY2025 | Sep 30, 2025 | $120.55M | – |
| FY2024 | Sep 30, 2024 | -$584.18M | – |
| FY2023 | Sep 30, 2023 | -$194.30M | – |
| FY2022 | Sep 30, 2022 | -$169.81M | – |
| FY2021 | Sep 30, 2021 | -$142.44M | – |
| FY2020 | Sep 30, 2020 | -$88.96M | -239.2% |
| FY2019 | Sep 30, 2019 | $63.89M | – |
| FY2018 | Sep 30, 2018 | -$52.94M | – |
| FY2017 | Sep 30, 2017 | -$34.01M | – |
| FY2016 | Sep 30, 2016 | -$78.48M | – |
| FY2015 | Sep 30, 2015 | -$93.64M | – |
| FY2014 | Sep 30, 2014 | -$51.93M | – |
| FY2013 | Sep 30, 2013 | -$22.84M | – |
| FY2012 | Sep 30, 2012 | -$19.34M | – |
| FY2011 | Sep 30, 2011 | -$9.56M | – |
| FY2010 | Sep 30, 2010 | -$5.56M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ3 2026 | Sep 30, 2026 | -$430.03M | -958.2% |
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | -$163.89M | – |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | -$135.36M | -135.0% |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | $46.81M | – |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | $50.11M | – |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | -$159.75M | – |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | $386.80M | – |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | -$156.61M | – |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | -$157.60M | – |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | -$171.74M | – |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | -$122.09M | -342.4% |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | -$132.75M | – |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | -$105.03M | – |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | -$99.80M | – |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | $50.37M | +15.1% |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | -$39.83M | – |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | -$81.63M | – |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | -$70.71M | – |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | $43.75M | – |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | -$61.22M | – |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | -$62.78M | – |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | -$30.27M | – |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | -$26.73M | – |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | -$22.65M | – |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | -$48.82M | -576.0% |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | -$14.85M | -177.4% |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | -$21.34M | -193.8% |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | -$4.05M | -134.6% |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | $10.26M | – |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | $19.17M | – |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | $22.76M | – |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | $11.70M | – |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | -$11.64M | – |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | -$14.74M | – |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | -$13.88M | – |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | -$12.67M | – |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | -$10.80M | – |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | -$4.55M | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | -$4.94M | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | -$13.72M | – |
See a number that looks wrong?